Pliant Therapeutics Inc (PLRX)

12:22 PM

Pliant Therapeutics: An Activist On Deck - Seeking Alpha

12:22 PM

Apr 02, 2025

symbol__ Stock Quote Price and Forecast - CNN

Apr 02, 2025

Apr 01, 2025

PLRX stock touches 52-week low at $1.25 amid sharp annual decline - Investing.com India

Apr 01, 2025

Mar 30, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire

Mar 30, 2025

Mar 27, 2025

PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know - MSN

Mar 27, 2025

Mar 26, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX - GlobeNewswire

Mar 26, 2025

Mar 26, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics – PLRX - MENAFN.COM

Mar 26, 2025

Mar 23, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant ... - Bluefield Daily Telegraph

Mar 23, 2025

Mar 23, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire Inc.

Mar 23, 2025

Mar 21, 2025

TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Pliant Therapeutics Inc - GuruFocus

Mar 21, 2025

Mar 21, 2025

Pliant discontinues Phase 2b/3 trial of IPF treatment bexotegrast - Pulmonary Fibrosis News

Mar 21, 2025

Mar 21, 2025

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus.com

Mar 21, 2025

Mar 19, 2025

Pliant Therapeutics (NASDAQ:PLRX) Receives “Neutral” Rating from HC Wainwright - Defense World

Mar 19, 2025

Mar 17, 2025

Pliant Therapeutics Announces Interim Phase 1 Data for - GlobeNewswire

Mar 17, 2025

Mar 17, 2025

Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types - Benzinga

Mar 17, 2025

Mar 17, 2025

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Markets Insider

Mar 17, 2025

Mar 17, 2025

Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial - Marketscreener.com

Mar 17, 2025

Mar 14, 2025

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’ - Yahoo Finance

Mar 14, 2025

Mar 14, 2025

Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms - Fierce Biotech

Mar 14, 2025

Mar 13, 2025

Pliant Therapeutics adopts shareholder rights plan By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals

Mar 13, 2025

Mar 13, 2025

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - The Malaysian Reserve

Mar 13, 2025

Mar 13, 2025

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus

Mar 13, 2025

Mar 13, 2025

Pliant Therapeutics Signs Shareholder Rights Agreement -March 13, 2025 at 08:32 am EDT - Marketscreener.com

Mar 13, 2025

Mar 13, 2025

Pliant Therapeutics adopts shareholder rights plan - Investing.com India

Mar 13, 2025

Mar 13, 2025

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - The Manila Times

Mar 13, 2025

Mar 13, 2025

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder Interests - Nasdaq

Mar 13, 2025

Mar 13, 2025

Pliant Therapeutics Shields Against Hostile Takeover with Strategic Rights Plan - StockTitan

Mar 13, 2025

Mar 09, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics - MENAFN.COM

Mar 09, 2025

Mar 06, 2025

Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF - MSN

Mar 06, 2025

Mar 06, 2025

Pliant Therapeutics (NASDAQ:PLRX) Cut to “Hold” at Leerink Partnrs - Defense World

Mar 06, 2025

Mar 05, 2025

Leerink Partners Downgrades Pliant Therapeutics (MUN:9PT) - Nasdaq

Mar 05, 2025

Mar 05, 2025

If You Don’t Bullish On Pliant Therapeutics Inc (NASDAQ: PLRX) Now, You’ll Regret Your Decision Later - Stocks Register

Mar 05, 2025

Mar 05, 2025

Pliant halts lung fibrosis trial amid safety concerns - The Pharma Letter

Mar 05, 2025

Mar 05, 2025

Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $3.00 by Analysts at Royal Bank of Canada - Defense World

Mar 05, 2025

Mar 04, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX - PR Newswire

Mar 04, 2025

Mar 04, 2025

Leerink Partners Downgrades Pliant Therapeutics (PLRX) - MSN

Mar 04, 2025

Mar 04, 2025

Pliant Therapeutics stock tumbles amid IPF trial cancellation - MSN

Mar 04, 2025

Mar 04, 2025

Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future - Benzinga

Mar 04, 2025

Mar 04, 2025

Hold Rating on Pliant Therapeutics Amid Trial Discontinuation and Safety Concerns - TipRanks

Mar 04, 2025

Mar 04, 2025

Pliant downgraded at Stifel on bexotegrast trial discontinuation - MSN

Mar 04, 2025